GlassScriptPhysician profile
Khalid M Shumburo
NPI 1952379737
$1,007.51
in general payments reported to CMS, 2019-2025
18 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $45.79 · 2021: $38.83 · 2022: $36.08 · 2023: $237 · 2024: $124 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $490 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $490.11 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $173.20 | 2020-2025 | Acthar |
| Amgen INC. | $140.00 | 2019-2025 | Tavneos, Aranesp, Parsabiv |
| Fresenius USA Marketing, INC. | $120.84 | 2023-2024 | Velphoro |
| Bard Peripheral Vascular, INC. | $107.83 | 2019 | |
| Akebia Therapeutics INC | $94.15 | 2019 | |
| Vifor Pharma, INC. | $87.28 | 2020-2023 | Veltassa, Korsuva |
| Mallinckrodt Enterprises LLC | $56.04 | 2019 | |
| Novartis Pharmaceuticals Corporation | $37.16 | 2025 | |
| Aurinia Pharma U.S., INC. | $28.23 | 2023 | Lupkynis |
| Travere Therapeutics, INC. | $26.03 | 2023 | |
| Recor Medical INC | $22.49 | 2025 | Paradise Ultrasound Renal Denervation System |
| Glaxosmithkline, LLC. | $22.09 | 2023 | Jesduvroq |
| Horizon Therapeutics Plc | $21.62 | 2023 | Tepezza |
| Calliditas Therapeutics US INC. | $20.12 | 2022 | |
| Lilly USA, LLC | $19.84 | 2024 | Jardiance |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $17.05 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.54 | 2024 | Jynarque |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$345,270.02 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Shumburo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.